IP Library › Patent Application 14032505
Patent Application
App. No. 14/032,505

Glycosaminoglycan Composition and Method for Treatment and Prevention of Interstitial Cystitis

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/032,505
Abstract

The invention provides compositions and methods useful for the treatment and/or prevention of interstitial cystitis and/or a related urinary tract condition in man or in animals. Specifically, provided are compositions specially formulated for direct instillation into the bladder and/or parenteral use in the treatment and/or prevention of interstitial cystitis. Compositions adapted for direct instillation into the bladder and/or for systemic administration are provided comprised of therapeutic amounts of: chondroitin sulfate in combination with hyaluronan (hyaluronic acid) are provided. Compositions adapted for direct instillation into the bladder and/or for systemic administration are also provided comprised of therapeutic amounts of: chondroitin sulfate, hyaluronan (hyaluronic acid) and N-acetyl D-glucosamine.

Claims (9)

1 . A composition formulated for direct bladder instillation and for treatment of interstitial cystitis or a related urinary tract condition in man or in animals consisting essentially of an effective amount of chondroitin sulfate and hyaluronan.

2 . The composition of claim 1 , wherein said chondroitin sulfate is CS4 chondroitin sulfate.

3 . The composition of claim 1 , wherein said chondroitin sulfate is CS6 chondroitin sulfate.

4 . The composition of claim 1 , wherein said chondroitin sulfate is a mixture of CS4 chondroitin sulfate and CS6 chondroitin sulfate.

5 . The composition of claim 1 , where said effective amount of chondroitin sulfate is between about 0.5 grams to about 1.5 grams per unit dose of the composition.

6 . The composition of claim 1 , where said effective amount of hyaluronan is about 10 mg to about 50 mg of hyaluronan per unit dose of the composition per unit dose of the composition.

7 . The composition of claim 1 , further comprises one or more excipients to facilitate the treatment.

8 . The composition of claim 1 , wherein said composition is a sterile solution.

9 . The composition of claim 1 , wherein said composition is a sterile suspension.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2017
From: ARTHRODYNAMIC TECHNOLOGIES, ANIMAL HEALTH DIVISION, INC.
To: ARTHRODYNAMIC HOLDINGS, LLC
Reel/Frame 040854/0031 →